In:
International Journal of Cancer, Wiley, Vol. 141, No. 12 ( 2017-12-15), p. 2423-2429
Abstract:
What's new? Pancreatic cancer is notoriously difficult to catch early. Prostaglandin‐E2 (PGE2) sometimes heralds the onset of cancer via the COX‐2 pathway. Overexpression of COX‐2, and the resulting overproduction of PGE2, can promote proliferation and inhibit apoptosis. Because PGE2 metabolites can be detected in urine, researchers have looked for an association between these molecules and various cancers. They have previously found that increased PGE2 metabolites in urine is associated with increased risk of colorectal cancer, gastric cancer and breast cancer. Now, new data reveal that prostaglandin‐E2 metabolites in urine can indeed signal an increased risk of pancreatic cancer.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8